Business Wire09.28.20
AtriCure Inc., an innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, announced that Andy Wade is stepping down from the position of chief financial officer (CFO) for personal reasons and moving into an advisory role through March 5, 2021. Angie Wirick, current vice president of Finance, has been promoted to CFO.
“On behalf of our team at AtriCure and our Board of Directors, I want to thank Andy for his contributions to our company over the past 13 years,” said Michael Carrel, president and CEO of AtriCure. “Andy has been instrumental to our global success and position of financial strength. Through his strong leadership, we achieved critical milestones to build AtriCure’s foundation and position our company for accelerated growth. These accomplishments have propelled our company to new levels of success and created significant shareholder value.”
“I am honored to have been a part of a tremendous team and world-class culture at AtriCure,” said Wade. “It has been a true privilege to work alongside colleagues who are passionately committed to our mission of improving patient lives and to see the growth of our impact in reducing the Afib epidemic around the world. While stepping down was a difficult decision, I am looking forward to moving into an advisory role and spending more time with my family.”
Wirick joined AtriCure in July 2014 and most recently has been the vice president of Finance, responsible for the global accounting and finance functions of the company. Before AtriCure, Wirick spent 12 years at Deloitte & Touche LLP in managerial roles and began her career at Arthur Andersen LLP. Wirick is a certified public accountant and earned a bachelor of science degree in accounting from the University of Dayton.
Carrel stated, “We are excited to have Angie as our new CFO. Angie has been an integral part of our team for six years. I congratulate Angie on the new role and look forward to continuing to work with her on our strategic initiatives and leading the company into the future.”
“On behalf of our team at AtriCure and our Board of Directors, I want to thank Andy for his contributions to our company over the past 13 years,” said Michael Carrel, president and CEO of AtriCure. “Andy has been instrumental to our global success and position of financial strength. Through his strong leadership, we achieved critical milestones to build AtriCure’s foundation and position our company for accelerated growth. These accomplishments have propelled our company to new levels of success and created significant shareholder value.”
“I am honored to have been a part of a tremendous team and world-class culture at AtriCure,” said Wade. “It has been a true privilege to work alongside colleagues who are passionately committed to our mission of improving patient lives and to see the growth of our impact in reducing the Afib epidemic around the world. While stepping down was a difficult decision, I am looking forward to moving into an advisory role and spending more time with my family.”
Wirick joined AtriCure in July 2014 and most recently has been the vice president of Finance, responsible for the global accounting and finance functions of the company. Before AtriCure, Wirick spent 12 years at Deloitte & Touche LLP in managerial roles and began her career at Arthur Andersen LLP. Wirick is a certified public accountant and earned a bachelor of science degree in accounting from the University of Dayton.
Carrel stated, “We are excited to have Angie as our new CFO. Angie has been an integral part of our team for six years. I congratulate Angie on the new role and look forward to continuing to work with her on our strategic initiatives and leading the company into the future.”
